Cargando…

Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway

BACKGROUND: Hepatic stellate cell (HSC) hyperactivation is a central link in liver fibrosis development. HSCs perform aerobic glycolysis to provide energy for their activation. Focal adhesion kinase (FAK) promotes aerobic glycolysis in cancer cells or fibroblasts, while FAK-related non-kinase (FRNK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Tao, Li, Yuan-Qing-Xiao, Zhou, Ming-Yu, Hu, Rui-Han, Zou, Gao-Liang, Li, Jian-Chao, Feng, Shu, Liu, Yong-Mei, Xin, Chang-Qin, Zhao, Xue-Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793014/
https://www.ncbi.nlm.nih.gov/pubmed/35125823
http://dx.doi.org/10.3748/wjg.v28.i1.123
_version_ 1784640504223236096
author Huang, Tao
Li, Yuan-Qing-Xiao
Zhou, Ming-Yu
Hu, Rui-Han
Zou, Gao-Liang
Li, Jian-Chao
Feng, Shu
Liu, Yong-Mei
Xin, Chang-Qin
Zhao, Xue-Ke
author_facet Huang, Tao
Li, Yuan-Qing-Xiao
Zhou, Ming-Yu
Hu, Rui-Han
Zou, Gao-Liang
Li, Jian-Chao
Feng, Shu
Liu, Yong-Mei
Xin, Chang-Qin
Zhao, Xue-Ke
author_sort Huang, Tao
collection PubMed
description BACKGROUND: Hepatic stellate cell (HSC) hyperactivation is a central link in liver fibrosis development. HSCs perform aerobic glycolysis to provide energy for their activation. Focal adhesion kinase (FAK) promotes aerobic glycolysis in cancer cells or fibroblasts, while FAK-related non-kinase (FRNK) inhibits FAK phosphorylation and biological functions. AIM: To elucidate the effect of FRNK on liver fibrosis at the level of aerobic glycolytic metabolism in HSCs. METHODS: Mouse liver fibrosis models were established by administering CCl(4), and the effect of FRNK on the degree of liver fibrosis in the model was evaluated. Transforming growth factor-β1 was used to activate LX-2 cells. Tyrosine phosphorylation at position 397 (pY397-FAK) was detected to identify activated FAK, and the expression of the glycolysis-related proteins monocarboxylate transporter 1 (MCT-1) and enolase1 (ENO1) was assessed. Bioinformatics analysis was performed to predict putative binding sites for c-myc in the ENO1 promoter region, which were validated with chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. RESULTS: The pY397-FAK level was increased in human fibrotic liver tissue. FRNK knockout promoted liver fibrosis in mouse models. It also increased the activation, migration, proliferation and aerobic glycolysis of primary hepatic stellate cells (pHSCs) but inhibited pHSC apoptosis. Nevertheless, opposite trends for these phenomena were observed after exogenous FRNK treatment in LX-2 cells. Mechanistically, the FAK/Ras/c-myc/ENO1 pathway promoted aerobic glycolysis, which was inhibited by exogenous FRNK. CONCLUSION: FRNK inhibits aerobic glycolysis in HSCs by inhibiting the FAK/Ras/c-myc/ENO1 pathway, thereby improving liver fibrosis. FRNK might be a potential target for liver fibrosis treatment.
format Online
Article
Text
id pubmed-8793014
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-87930142022-02-03 Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway Huang, Tao Li, Yuan-Qing-Xiao Zhou, Ming-Yu Hu, Rui-Han Zou, Gao-Liang Li, Jian-Chao Feng, Shu Liu, Yong-Mei Xin, Chang-Qin Zhao, Xue-Ke World J Gastroenterol Basic Study BACKGROUND: Hepatic stellate cell (HSC) hyperactivation is a central link in liver fibrosis development. HSCs perform aerobic glycolysis to provide energy for their activation. Focal adhesion kinase (FAK) promotes aerobic glycolysis in cancer cells or fibroblasts, while FAK-related non-kinase (FRNK) inhibits FAK phosphorylation and biological functions. AIM: To elucidate the effect of FRNK on liver fibrosis at the level of aerobic glycolytic metabolism in HSCs. METHODS: Mouse liver fibrosis models were established by administering CCl(4), and the effect of FRNK on the degree of liver fibrosis in the model was evaluated. Transforming growth factor-β1 was used to activate LX-2 cells. Tyrosine phosphorylation at position 397 (pY397-FAK) was detected to identify activated FAK, and the expression of the glycolysis-related proteins monocarboxylate transporter 1 (MCT-1) and enolase1 (ENO1) was assessed. Bioinformatics analysis was performed to predict putative binding sites for c-myc in the ENO1 promoter region, which were validated with chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. RESULTS: The pY397-FAK level was increased in human fibrotic liver tissue. FRNK knockout promoted liver fibrosis in mouse models. It also increased the activation, migration, proliferation and aerobic glycolysis of primary hepatic stellate cells (pHSCs) but inhibited pHSC apoptosis. Nevertheless, opposite trends for these phenomena were observed after exogenous FRNK treatment in LX-2 cells. Mechanistically, the FAK/Ras/c-myc/ENO1 pathway promoted aerobic glycolysis, which was inhibited by exogenous FRNK. CONCLUSION: FRNK inhibits aerobic glycolysis in HSCs by inhibiting the FAK/Ras/c-myc/ENO1 pathway, thereby improving liver fibrosis. FRNK might be a potential target for liver fibrosis treatment. Baishideng Publishing Group Inc 2022-01-07 2022-01-07 /pmc/articles/PMC8793014/ /pubmed/35125823 http://dx.doi.org/10.3748/wjg.v28.i1.123 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Basic Study
Huang, Tao
Li, Yuan-Qing-Xiao
Zhou, Ming-Yu
Hu, Rui-Han
Zou, Gao-Liang
Li, Jian-Chao
Feng, Shu
Liu, Yong-Mei
Xin, Chang-Qin
Zhao, Xue-Ke
Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway
title Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway
title_full Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway
title_fullStr Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway
title_full_unstemmed Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway
title_short Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway
title_sort focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the fak/ras/c-myc/eno1 pathway
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793014/
https://www.ncbi.nlm.nih.gov/pubmed/35125823
http://dx.doi.org/10.3748/wjg.v28.i1.123
work_keys_str_mv AT huangtao focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT liyuanqingxiao focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT zhoumingyu focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT huruihan focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT zougaoliang focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT lijianchao focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT fengshu focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT liuyongmei focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT xinchangqin focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway
AT zhaoxueke focaladhesionkinaserelatednonkinaseamelioratesliverfibrosisbyinhibitingaerobicglycolysisviathefakrascmyceno1pathway